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Medicare beneficiaries aged ≥ 65 years, diagnosed with depression, and no history of 
falls/fractures in 2007 (Baseline Period). Cases were identified as patients with inci-
dent fractures following the baseline period. For each case, 4 age and sex-matched 
controls were selected using incidence density sampling. The primary outcome 
was an inpatient or outpatient claim for fractures, between January 1, 2008 and 
December 31, 2010. Anticholinergic exposure was defined using Anticholinergic 
Drug Scale (ADS). Prescription of level 2/3 anticholinergic medications 30 days pre-
ceding the event date formed the primary exposure. Conditional logistic regression 
model stratified on matched case-control sets was performed to assess the fracture 
risk, after controlling for other risk factors of the outcome. RESULTS: The study 
sample included 43,402 cases of fractures and 173,608 matched controls (Incidence 
Density 1:4). After adjusting for other risk factors, there was no difference in risk 
with high-level anticholinergic use compared to non-use (Relative Risk, RR 1.02; 95% 
Confidence Interval [CI], 1.00-1.04). The findings remained consistent across levels 
of anticholinergic potency (Level 2, RR 1.01, 95% CI, 0.98-1.06; Level 3, 95% CI, 1.03, 
0.99-1.07). CONCLUSIONS: Use of anticholinergic medications was not associated 
with a higher risk of fractures compared to no use among elderly residents with 
depression. Given their safety concerns, there is a need to further evaluate other 
adverse outcomes associated with anticholinergics in the elderly.
PMH3
THe iMPacT of alTernaTive anTiPsycHoTic MedicaTions on THe risk of 
adverse evenTs in PaTienTs TreaTed for scHizoPHrenia
Jiang Y., Park S., McCombs J.
University of Southern California, Los Angeles, CA, USA
OBJECTIVES: This study compares the risks of side effects [SE] associated with a 
broad of range of typical and atypical antipsychotics used to treat patients with 
schizophrenia. METHODS: Medical and pharmacy claims data from Humana from 
January 2007 to June 2013 were used to define episodes of antipsychotic drug therapy 
for patients with schizophrenia. Episodes were screened for a minimum of 180 days 
of pre-episode and 360 days of post-episode data, and for the existence of study SEs 
prior to the episode index date. Study samples ranged from N= 97,481 for rhabdomy-
olysis (RM) to N= 99,017 acute urinary retention (AUR). Other SE for analysis included 
acute kidney injury (AKI), hypotension, pneumonia (PNA), acute coronary syndrome 
(ACS) or ischemic stroke/cerebral infarction, and ventricular cardiac arrhythmia 
(VCA). Logistic regression models were used to estimate the impact of alternative 
antipsychotics on the risk of an emergent SE in the year following the initiation 
of treatment. The logistic models controlled for patient demographics, treatment 
history, concomitant use of antidepressants, mood stabilizers and anticonvulsants, 
and diagnostic and drug use profiles in the prior 6 months. Haloperidol was used as 
the comparison drug. RESULTS: Perphenazine and ziprasidone reduced the risk of 
acute cardiovascular events relative to haloperidol. The risk of acute kidney injury 
was significantly increased in patients taking aripiprazole, olanzapine, quetiapine, 
risperidone and ziprasidone relative to haloperidol. The risk of hypotension was 
elevated in chlorpromazine and quetiapine patients and reduced in those using pali-
peridone, perphenazine and thiothixene. The risk of AUR was increased in patients 
using fluphenazine, but reduced in patients using aripiprazole, risperidone and 
thiothixene. The risk of RM was increased by the use of fluphenazine and quetia-
pine while the risk of pneumonia was elevated for patients using chlorpromazine, 
clozapine, paliperidone and quetiapine. CONCLUSIONS: The risk of side effects 
varies widely across antipsychotic medications.
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OBJECTIVES: This study compares the risks of side effects [SE] associated with a broad 
of range of atypical and typical antipsychotics used to treatment patients with bipolar 
disorder. METHODS: Medical and pharmacy claims data from Humana from January 
2007 to June 2013 were used to define episodes of antipsychotic drug therapy for 
patients with bipolar disorder. Episodes were screened for a minimum of 180 days of 
pre-episode and 360 days of post-episode data, and for the existence of study SEs prior 
to the episode index date. Study samples ranged from N= 147,658 for rhabdomyolysis 
[RM] to N= 150,084 acute urinary retention [AUR]. Other SE for analysis included acute 
kidney injury [AKI], hypotension, pneumonia (PNA), acute coronary syndrome (ACS) 
or ischemic stroke/cerebral infarction, ventricular (tachy) arrhythmia (VCA). Logistic 
regression models were used to estimate the impact of alternative antipsychotics on 
the risk of an emergent SE in the year following the initiation of treatment. The logistic 
models controlled for patient demographics, treatment history, concomitant use of 
antidepressants, mood stabilizers and anticonvulsants, diagnostic and drug use pro-
files in the prior 6 months. Haloperidol was used as the comparison drug. RESULTS: 
Aripiprazole, ziprasidone and risperidone did not differentiate relative to haliperidol. 
Only fluphenazine increases the risk of cardiovascular events relative to heliperidol. 
All other SE impacts related to specific antipsychotics were related to kidney disorders 
or pneumonia. Chlorpromazine increased the risk of acute kidney injury, hypoten-
sion, rhabdomyolysis and pneumonia. Clozapine increased the risk of pneumonia. 
Olanzapine increased the risk of AKI and pneumonia but significantly decreased the 
risk of AUR. Paliparidone also increased the risk of PNA and decreased the risk of 
AUR. Quetiapine increased the risk of AKI while perphenazine decreased the risk of 
hypotension and thiothixene decreased the risk of AUR. CONCLUSIONS: The risk of 
side effects varies widely across antipsychotic medications.
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OBJECTIVES: The epidemiological evidence of panic disorder (PD) is limited and 
little is known about the treatment for PD in the real clinical setting. The aim of 
this study was to determine the prevalence of PD, and to investigate concurrent 
diseases and prescriptions in patients with PD using a Japanese healthcare insur-
ance claims database. METHODS: This was a retrospective cohort study in patients 
having at least one diagnosis record of PD (ICD-10 code: F41.0), extracted from the 
MinaCare claims database (MinaCare Co. Ltd, Japan). The annual prevalence was 
estimated based on claims of fiscal years of 2011 and 2012 (Apr to Mar). The study 
cohort to investigate concurrent diseases and prescribed drugs consists of newly 
diagnosed patients, which was defined as patients with no diagnosis record of PD 
within 6 months prior to the 1st diagnosis of PD in the database. RESULTS: The 
estimated annual prevalence of PD was approximately 0.3%. Higher prevalence was 
observed in females in their 20s, 30s and 40s. In 2,100 newly diagnosed PD patients, 
the common diseases recorded concurrently at 1st PD diagnosis were insomnia, 
depression and neurosis. The predominant drugs prescribed at 1st PD diagnosis 
were SSRIs and benzodiazepines, as recommended in the current guideline as 1st 
line treatment; however, the proportion of patients prescribed both SSRIs together 
with benzodiazepines was less than 40%, and almost half of the patients were not 
prescribed SSRIs at 1st PD diagnosis. This prescription trend showed no remarkable 
change during the 6 months post-diagnosis period. CONCLUSIONS: The estimated 
prevalence including gender difference and age distribution were consistent with 
previous studies of PD. However, the prescription at 1st PD diagnosis suggests the 
existence of a gap between the real-world practices and the guideline recommen-
dation. Further investigation is needed to identify possible factors having impact 
on adequate treatment of PD.
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OBJECTIVES: The prevalence of co-occurring depression in chronic obstructive 
pulmonary disease (COPD) is as high as 40% and associated with substantial nega-
tive outcomes. Prior studies have shown that combined treatment with psycho-
therapy and antidepressants is superior to antidepressant treatment alone in 
reducing depressive symptoms and improving quality of life. However, popula-
tion based studies on the patterns of depression treatment among individuals 
with co-occurring COPD and depression are limited. We examined the patterns 
of depression treatment in various subgroups of individuals with co-occurring 
COPD and depression. METHODS: We used a retrospective, cross-sectional study 
design, pooling data from the 2009 and 2011 Medical Expenditure Panel Survey 
(MEPS). The analytical sample consisted of 886 individuals aged 21 years or older, 
diagnosed with COPD and depression. We classified depression treatment into 
three mutually exclusive categories: no depression treatment; antidepressants 
use only; and psychotherapy in conjunction with antidepressants. We conducted 
chi-squared tests and multinomial logistic regressions to examine patterns of 
depression treatment by socio-demographic, medical conditions and health status 
characteristics of this population. RESULTS: Overall, 18.5% of the study population 
reported no treatment for depression, 72% reported antidepressants use only and 
only 9.5% reported the use of psychotherapy in conjunction with antidepressants. 
Females were significantly more likely than males to receive psychotherapy and 
antidepressants for depression treatment (AOR= 2.41, 95% CI= 1.21, 4.81). Uninsured 
individuals were less likely than individuals with private insurance in receiv-
ing combined treatment (AOR= 0.25, 95% CI= 0.08, 0.84). Individuals with fair/poor 
perceived mental health status were more likely to receive combined treatment 
than individuals reporting excellent/ very good mental health status (AOR= 4.19, 
95% CI= 1.59, 11.05). Those with anxiety were significantly more likely to receive 
combined treatment (AOR= 3.21, 95% CI= 1.62, 6.37). CONCLUSIONS: Future stud-
ies need to identify the barriers to combined treatment of depression with psy-
chotherapy and antidepressants among various subgroups of individuals with 
co-occurring COPD and depression.
PMH7
anTiPsycHoTics for TreaTMenT of PediaTric scHizoPHrenia: a 
sysTeMaTic review and neTwork MeTa-analysis of syMPToM 
conTrol, weigHT gain and disconTinuaTion due To adverse evenTs
Harvey R.C.1, Shields G.E.1, James A.C.2
1BresMed, Sheffield, UK, 2Oxford Health, Oxford, UK
OBJECTIVES: Few studies discuss the effectiveness and side effects of the use of 
antipsychotics in the pediatric population, despite the poor prognosis associated 
with the disorder, including high suicide risk. This study explores the efficacy of 
trialled antipsychotics for early-onset schizophrenia in order to determine which 
treatments are potentially efficacious in this population. METHODS: A systematic 
literature review was performed to identify trials conducted in children and ado-
lescents with schizophrenia that reported symptom control (efficacy) using the 
positive and negative syndrome scale (PANSS), a medical scale frequently used 
for assessing the schizophrenia symptom severity in trials. A Bayesian random 
effects network-meta-analysis was performed, synthesizing data for relevant out-
comes, including mean change from baseline in PANSS scores (including positive 
and negative subscales), weight gain and treatment discontinuation due to adverse 
events. RESULTS: Eleven studies were identified in the systematic review, and ten 
were included in the network meta-analysis. All treatments showed a greater reduc-
tion in PANSS scores at 6 weeks vs placebo; however, not all results were statisti-
cally significant. Haloperidol had the greatest reduction vs placebo; and treatment 
ranking probabilities suggested that haloperidol had the highest probability of being 
the best treatment in the network for reducing total PANSS scores. All treatments 
showed a trend of greater odds of discontinuing treatment due to adverse events vs 
placebo. However, pairwise comparisons were statistically non-significant. Nine out 
of thirteen treatments showed a trend of increased weight compared with placebo, 
